Valuation: BriaCell Therapeutics Corp.

Market Cap 2.99Cr 2.67Cr 2.49Cr 2.26Cr 4.26Cr 289.22Cr 4.29Cr 30Cr 12Cr 147.04Cr 11Cr 11Cr 472.22Cr P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 1.2Cr 1.07Cr 1Cr 90.98L 1.71Cr 116.35Cr 1.73Cr 12Cr 4.7Cr 59Cr 4.51Cr 4.42Cr 189.97Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.96%
Yield 2024 *
-
Yield 2025 -
14/09 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
11/09 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
08/09 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
02/09 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
24/08 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
06/08 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
05/08 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
16/07 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study MT
16/07 BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer CI
1 day-0.18%
1 week-6.72%
Current month-6.72%
1 month+17.32%
3 months+15.65%
6 months-5.95%
Current year-41.94%
1 week 5.63
Extreme 5.63
6.11
1 month 4.72
Extreme 4.72
6.23
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,200
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 65 16/02/2022
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Tax

Director

45,000 0.5173%
07/07/26 Tax

Director

15,000 0.1724%
07/07/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-6.72%-67.73%-99.50% 3.49Cr
+4.16%+4.16%+49.37%+94.17% 7.47TCr
+0.46%-1.16%+23.36%+79.34% 5.88TCr
+0.17%-1.16%+3.59%+34.55% 4.84TCr
+0.50%-1.77%+331.24%+702.20% 4.28TCr
-0.72%-4.04%+25.90%+29.94% 4.28TCr
+0.34%-0.34%+5.66%+109.35% 4.12TCr
-0.11%+1.96%+9.19%+52.66% 3.11TCr
-2.07%+1.16%+35.00%+26.28% 3.03TCr
-0.50%-3.37%-9.42%-14.35% 2.4TCr
Average +0.20%-0.40%+40.61%+101.46% 3.94TCr
Weighted average by Cap. +0.69%-0.54%+55.50%+130.18%

Financials

2024 2025
Net sales - -
Net income -47.91L -42.77L -39.9L -36.25L -68.31L -46Cr -68.83L -4.79Cr -1.87Cr -24Cr -1.8Cr -1.76Cr -76Cr -2.63Cr -2.35Cr -2.19Cr -1.99Cr -3.75Cr -254.59Cr -3.78Cr -26Cr -10Cr -129.43Cr -9.88Cr -9.66Cr -415.68Cr
Net Debt -9L -8L -7L -7L -12.29L -8.34Cr -12.38L -86.18L -33.68L -4.24Cr -32.36L -31.66L -14Cr -1.79Cr -1.59Cr -1.49Cr -1.35Cr -2.55Cr -172.87Cr -2.57Cr -18Cr -6.98Cr -88Cr -6.71Cr -6.56Cr -282.25Cr
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
07/26/07 CA$5.690 -0.18% 1,723
06/26/06 CA$5.700 -3.88% 3,627
05/26/05 CA$5.930 +3.13% 3,674
02/26/02 CA$5.750 -2.21% 4,650
01/26/01 CA$5.880 -3.61% 4,816

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BriaCell Therapeutics Corp.